Zobrazeno 1 - 10
of 412
pro vyhledávání: '"Brian E. Lacy"'
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 17 (2024)
Background: Constipation is characterized by symptoms of straining, hard stool, difficult evacuation, and infrequent bowel movements. Online surveys provide valuable information about patients’ perspectives, symptoms, management, treatment satisfac
Externí odkaz:
https://doaj.org/article/8784ab68f75d4a21a713d7ed5c1d4bb3
Autor:
Brian E. Lacy, William D. Chey, Michael S. Epstein, Syed M. Shah, Patrick Corsino, Linda R. Zeitzoff, Brooks D. Cash
Publikováno v:
BMC Gastroenterology, Vol 22, Iss 1, Pp 1-9 (2022)
Abstract Background A randomized, placebo-controlled clinical trial (FDREST) of a novel formulation of caraway oil and L-menthol (COLM-SST) demonstrated symptom relief in patients with functional dyspepsia (FD). Two follow-up studies were conducted t
Externí odkaz:
https://doaj.org/article/24af56e881034192ac8cb1e8a7a1d9c1
Autor:
Javier Cid-Ruzafa, Brian E. Lacy, Anna Schultze, Mai Duong, Yi Lu, Mireia Raluy-Callado, Robert Donaldson, Darren Weissman, Ainhoa Gómez-Lumbreras, Dan Ouchi, Maria Giner-Soriano, Rosa Morros, Ahunna Ukah, Daniel Pohl
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 15 (2022)
Introduction: Linaclotide is approved for adults with moderate-to-severe irritable bowel syndrome (IBS) with constipation (IBS-C). Linaclotide is not indicated for weight loss or for patients with inflammatory bowel disease (IBD); it is contraindicat
Externí odkaz:
https://doaj.org/article/293ffc018ae94683aad4234c5301a1d6
Autor:
Hassan Ghoz, Fernando F. Stancampiano, Jose R. Valery, Katie Nordelo, Balkishan Malviya, Brian E. Lacy, Dawn Francis, Kenneth DeVault, Ernest Bouras, Murli Krishna, William C. Palmer
Publikováno v:
Endoscopy International Open, Vol 09, Iss 08, Pp E1234-E1242 (2021)
Background and study aim The clinical impact of eosinophilic esophagitis (EoE) limited to the distal esophagus (Lim-EE) vs. diffuse involvement (Dif-EE) is unknown. This study compared clinical characteristics and outcomes of Lim-EE vs. Dif-EE. Patie
Externí odkaz:
https://doaj.org/article/5266266cd12d4a0d8728f23873779913
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 14 (2021)
Background: Eluxadoline, a United States Food and Drug Administration (FDA)-approved treatment for irritable bowel syndrome with diarrhea (IBS-D), underwent a change to its US prescribing information on 21 April 2017, contraindicating it in patients
Externí odkaz:
https://doaj.org/article/b073d1d0c7f0469d9aa1ab43af5ba6a1
Autor:
David J. Cangemi, Brian E. Lacy
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 12 (2019)
Irritable bowel syndrome (IBS) is a common gastrointestinal (GI) condition involving numerous potential causative factors (e.g. alterations in gut microbiota, motility, brain–gut axis). Several interventions are available for the management of pati
Externí odkaz:
https://doaj.org/article/549c85be1b4a4f03a9d29f646e18bffe
Autor:
Brian E. Lacy, Lucinda A. Harris, Lin Chang, Susan Lucak, Catherine Gutman, Leonard S. Dove, Paul S. Covington, Anthony Lembo
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 12 (2019)
Background: Irritable bowel syndrome with diarrhea (IBS-D) is a prevalent gastrointestinal (GI) disorder with a varied presentation, often overlapping with other GI and non-GI disorders. Eluxadoline is a locally active mixed µ- and κ-opioid recepto
Externí odkaz:
https://doaj.org/article/14c088d70438411f8b19cdbc07a52190
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 11 (2018)
Background: Alosetron is approved to treat women with severe IBS and diarrhea (IBS-D) who have failed standard therapy. In our study, we aimed to evaluate alosetron efficacy using new US Food and Drug Administration (FDA) endpoints and utilization in
Externí odkaz:
https://doaj.org/article/ecbfd7e16ae5449da4cd9c89d60b4ece
Autor:
Brian E. Lacy, Nihal K. Patel
Publikováno v:
Journal of Clinical Medicine, Vol 6, Iss 11, p 99 (2017)
Functional gastrointestinal disorders (FGIDs) account for at least 40% of all referrals to gastroenterologists. Of the 33 recognized adult FGIDs, irritable bowel syndrome (IBS) is the most prevalent, with a worldwide prevalence estimated at 12%. IBS
Externí odkaz:
https://doaj.org/article/5c9391abd3494183884381eb7ff31ac6
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 2 (2009)
Irritable bowel syndrome (IBS) is a highly prevalent functional bowel disorder routinely encountered by healthcare providers. Although not life-threatening, this chronic disorder reduces patients' quality of life and imposes a significant economic bu
Externí odkaz:
https://doaj.org/article/ce4317f44f7f43f594aa723ecac49fa5